September 30, 2008
CSL Behring Solicits Proposals for LEAD Grants to Support Patient Advocacy Efforts
CSL Behring, a global leader in the plasma protein biotherapeutics industry, is soliciting grants to support patient access to care through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program is committed to funding grassroots advocacy efforts in the United States by providing grants to patient organizations dedicated to helping people with rare diseases who use plasma-derived or recombinant therapies to manage their conditions.
"CSL Behring is proud to support patient organizations in their advocacy initiatives through LEAD grants," said Dennis Jackman, Senior Vice President, Public Affairs. "CSL Behring LEAD grants supplement existing resources to ensure that patient organizations are able to address complex legislative and public policy issues."This fall's grants will be the second round of patient advocacy grants to be awarded through the LEAD Program. Last spring, CSL Behring awarded seven LEAD grants to patient advocacy organizations. These grants funded grassroots advocacy initiatives, including developing state standards of care legislation, improving insurance access and mobilizing patient populations.
In order to qualify for a LEAD grant, an organization must be a recognized patient advocacy group representing individuals who use plasma/recombinant therapies to treat bleeding disorders, immune disorders, Alpha-1 deficiency or other conditions. The organization, which should either be planning to address an advocacy issue or currently addressing such an issue, must also be a non-profit with 501(c)(3) tax status.
The deadline for submitting applications is October 31, 2008. Applications, specific criteria for applying, and additional information about the LEAD program are available on the CSL Behring Web site at www.cslbehring.com/leadgrants. The grants will be awarded to patient organizations, which adequately demonstrate that financial assistance will help realize important local or state advocacy initiatives.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufacturers and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.
CSL Behring operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.